Company registration number 13991002 (England and Wales)
RHODIUM PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
RHODIUM PHARMA LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
RHODIUM PHARMA LTD
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
280,000
320,000
Tangible assets
4
12,177
14,850
292,177
334,850
Current assets
Stocks
26,250
24,750
Debtors
5
166,814
248,103
Cash at bank and in hand
200,238
387,464
393,302
660,317
Creditors: amounts falling due within one year
6
(763,645)
(1,063,520)
Net current liabilities
(370,343)
(403,203)
Total assets less current liabilities
(78,166)
(68,353)
Provisions for liabilities
(3,044)
-
0
Net liabilities
(81,210)
(68,353)
Capital and reserves
Called up share capital
6
6
Profit and loss reserves
(81,216)
(68,359)
Total equity
(81,210)
(68,353)

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 13 November 2025 and are signed on its behalf by:
Kamran Sarwar
Director
Company registration number 13991002 (England and Wales)
RHODIUM PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Rhodium Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 65 Woolmore Road, Birmingham, UK, B23 7EB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services

provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair

value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.3
Intangible fixed assets - goodwill

Goodwill is being written off in equal annual instalments over its estimated economic life of 10 years.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
18% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

RHODIUM PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 3 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
6
6
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
400,000
Amortisation and impairment
At 1 April 2024
80,000
Amortisation charged for the year
40,000
At 31 March 2025
120,000
Carrying amount
At 31 March 2025
280,000
At 31 March 2024
320,000
RHODIUM PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2024 and 31 March 2025
21,318
Depreciation and impairment
At 1 April 2024
6,468
Depreciation charged in the year
2,673
At 31 March 2025
9,141
Carrying amount
At 31 March 2025
12,177
At 31 March 2024
14,850
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
125,503
209,261
Other debtors
41,311
38,842
166,814
248,103
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
141,744
70,478
Corporation tax
10,147
3,567
Other taxation and social security
2,569
2,367
Other creditors
609,185
987,108
763,645
1,063,520
RHODIUM PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
7
Related Party Disclosures

As at 31 March 2025 the following balances, included in other debtor due within one year, was due from related company:

 

Billesley Pharma Ltd: £10,000

 

The above balance is repayable on demand.

 

As at 31 March 2025 the following balances, included in other creditor due within one year, was due to related company:

 

Pharmeasy Ltd: £4,500

 

The above balance is payable on demand.

8
Ultimate Controlling Party

The controlling party is Kamran Sarwar.

2025-03-312024-04-01falsefalsefalse13 November 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityKamran SarwarMaryam Sarwar139910022024-04-012025-03-31139910022025-03-31139910022024-03-3113991002core:NetGoodwill2025-03-3113991002core:NetGoodwill2024-03-3113991002core:OtherPropertyPlantEquipment2025-03-3113991002core:OtherPropertyPlantEquipment2024-03-3113991002core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3113991002core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3113991002core:ShareCapital2025-03-3113991002core:ShareCapital2024-03-3113991002core:RetainedEarningsAccumulatedLosses2025-03-3113991002core:RetainedEarningsAccumulatedLosses2024-03-3113991002bus:Director12024-04-012025-03-3113991002core:FurnitureFittings2024-04-012025-03-31139910022023-04-012024-03-3113991002core:NetGoodwill2024-03-3113991002core:NetGoodwill2024-04-012025-03-3113991002core:OtherPropertyPlantEquipment2024-03-3113991002core:OtherPropertyPlantEquipment2024-04-012025-03-3113991002core:CurrentFinancialInstruments2025-03-3113991002core:CurrentFinancialInstruments2024-03-3113991002core:WithinOneYear2025-03-3113991002core:WithinOneYear2024-03-3113991002bus:PrivateLimitedCompanyLtd2024-04-012025-03-3113991002bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3113991002bus:FRS1022024-04-012025-03-3113991002bus:AuditExemptWithAccountantsReport2024-04-012025-03-3113991002bus:Director22024-04-012025-03-3113991002bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP